中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 8
Aug.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(8): 1705-1709

Urgent scientific issues to be solved in clinical trials of capsid assembly modulator combined with nucleos(t)ide analogues for the treatment of chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2022.08.001
  • 1.

    Hepatology Institute, Peking University People's Hospital, Beijing 100044, China

  • 2.

    Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China

More Information
  • Corresponding author: LU Fengmin, lu.fengmin@hsc.pku.edu.cn(ORCID: 0000-0002-1832-3209); ZHUANG Hui, zhuangbmu@126.com(ORCID: 0000-0001-9119-6325)
  • Received Date: 2022-04-20
  • Accepted Date: 2022-05-20
  • Published Date: 2022-08-20
    Abstract
  • Chronic hepatitis B virus (HBV) infection is the main cause of viral hepatitis, liver cirrhosis, and primary liver cancer. At present, nucleos(t)ide analogues (NUC) and pegylated interferon α used in clinical practice cannot directly target covalently closed circular DNA, and it is difficult to achieve clinical cure of chronic hepatitis B patients; therefore, it is urgently needed to develop direct-acting antiviral agents targeting all stages of the HBV replication cycle. Capsid assembly modulator (CpAM) targets the assembly of viral capsids through various mechanisms, thereby exerting a direct-acting antiviral effect. Its combination with NUC should have a good synergistic antiviral effect, but the results of existing clinical trials have shown that chronic hepatitis B patients who received a limited course of antiviral therapy with CpAM and NUC all experienced off-therapy viral rebound. Based on the mechanism of action of these two types of drugs, this article provides a reasonable explanation for the above clinical trial results and points out that a longer course of antiviral therapy with CpAM and NUC may be needed in the future clinical trials with safe drug withdrawal as the end point of observation, so as to deplete or silence the pool of covalently closed circular DNA and increase the possibility of safe drug withdrawal in CHB patients. In addition, further studies are needed to explore antiviral therapeutic strategies with a combination of multiple targets.

     

    • FullText(HTML)
  • loading
    • References(50)
  • [1]
    World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016-2021: actions for impact[EB/OL]. WHO, 2021. https://www.who.int/publications/i/item/9789240027077.
    [2]
    Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6.
    [3]
    LIU J, LIANG W, JING W, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238. DOI: 10.2471/BLT.18.219469.
    [4]
    World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis[EB/OL]. WHO, 2016. https://www.who.int/publications/i/item/WHO-HIV-2016.06.
    [5]
    Polaris Observatory Collaborators. HBV progress towards coverage targets[EB/OL]. (2021-10-04)[2022-02-06]. https://cdafound.org/polaris-countries-dashboard/.
    [6]
    NING Q, WU D, WANG GQ, et al. Roadmap to functional cure of chronic hepatitis B: An expert consensus[J]. J Viral Hepat, 2019, 26(10): 1146-1155. DOI: 10.1111/jvh.13126.
    [7]
    MO Z, GAN W, ZHAO Q, et al. Functional cure of chronic hepatitis B: Efforts and prospects[J]. Liver Research, 2020, 4(1): 1-4. DOI: 10.1016/j.livres.2020.02.005.
    [8]
    KIM GA, LIM YS, AN J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability[J]. Gut, 2014, 63(8): 1325-1332. DOI: 10.1136/gutjnl-2013-305517.
    [9]
    LIU Y, LIU H, HU Z, et al. Hepatitis B virus virions produced under nucleos(t)ide analogue treatment are mainly not infectious because of irreversible DNA chain termination[J]. Hepatology, 2020, 71(2): 463-476. DOI: 10.1002/hep30844.
    [10]
    Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [11]
    LI GX, LIU H, JIANG QQ, et al. The importance of selection of evaluation indicators for antiviral therapy of chronic hepatitis B based on the clinical trial results of a CpAM[J]. Chin J New Clin Med, 2021, 14(12): 1163-1168. DOI: 10.3969/j.issn.1674-3806.2021.12.02.

    李桂馨, 刘慧, 姜倩倩, 等. 从某核衣壳抑制剂临床试验结果看慢性乙肝抗病毒治疗评价指标选择的重要性[J]. 中国临床新医学, 2021, 14(12): 1163-1168. DOI: 10.3969/j.issn.1674-3806.2021.12.02.
    [12]
    MEIER MA, CALABRESE D, SUSLOV A, et al. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load[J]. J Hepatol, 2021, 75(4): 840-847. DOI: 10.1016/j.jhep.2021.04.051.
    [13]
    ALEXOPOULOU A, KARAYIANNIS P. HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection[J]. World J Gastroenterol, 2014, 20(24): 7644-7652. DOI: 10.3748/wjg.v20.i24.7644.
    [14]
    WEI L, PLOSS A. Hepatitis B virus cccDNA is formed through distinct repair processes of each strand[J]. Nat Commun, 2021, 12(1): 1591. DOI: 10.1038/s41467-021-21850-9.
    [15]
    WEI L, PLOSS A. Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation[J]. Nat Microbiol, 2020, 5(5): 715-726. DOI: 10.1038/s41564-020-0678-0.
    [16]
    MARCHETTI AL, ZHANG H, KIM ES, et al. Proteomic analysis of nuclear hepatitis B virus relaxed circular DNA-associated proteins identifies UV-Damaged DNA binding protein as a host factor involved in covalently closed circular DNA formation[J]. J Virol, 2022, 96(2): e0136021. DOI: 10.1128/JVI.01360-21.
    [17]
    CAI D, YAN R, XU JZ, et al. Characterization of the termini of cytoplasmic hepatitis B virus deproteinated relaxed circular DNA[J]. J Virol, 2020, 95(1): e00922-2. DOI: 10.1128/JVI.00922-20.
    [18]
    PETERSEN J, THOMPSON AJ, LEVRERO M. Aiming for cure in HBV and HDV infection[J]. J Hepatol, 2016, 65(4): 835-848. DOI: 10.1016/j.jhep.2016.05.043.
    [19]
    WANG J, HUANG H, LIU Y, et al. HBV genome and life cycle[J]. Adv Exp Med Biol, 2020, 1179: 17-37. DOI: 10.1007/978-981-13-9151-4_2.
    [20]
    KO C, CHAKRABORTY A, CHOU WM, et al. Hepatitis B virus genome recycling and De novo secondary infection events maintain stable cccDNA levels[J]. J Hepatol, 2018, 69(6): 1231-1241. DOI: 10.1016/j.jhep.2018.08.012.
    [21]
    LUCIFORA J, ARZBERGER S, DURANTEL D, et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection[J]. J Hepatol, 2011, 55(5): 996-1003. DOI: 10.1016/j.jhep.2011.02.015.
    [22]
    SAEED U, KIM J, PIRACHA ZZ, et al. Parvulin 14 and parvulin 17 bind to HBx and cccDNA and upregulate hepatitis B virus replication from cccDNA to virion in an HBx-dependent manner[J]. J Virol, 2019, 93(6): e01840-18. DOI: 10.1128/JVI.01840-18.
    [23]
    HUANG Q, ZHOU B, CAI D, et al. Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients[J]. Hepatology, 2021, 73(1): 41-52. DOI: 10.1002/hep.31240.
    [24]
    GAO L, MAO TH, PENG SW, et al. A short half-life of cccDNA offer or ignite hope for hepatitis B cure under nucleos(t)ide analogues treatment[J]. Chin J Hepatol, 2022, 30(1): 99-102. DOI: 10.3760/cma.j.cn501113-20200527-00277.

    高林, 毛天皓, 彭思雯, 等. 核苷(酸)治疗下较短的cccDNA半衰期或给"乙肝治愈"点燃希望[J]. 中华肝脏病杂志, 2022, 30(1): 99-102. DOI: 10.3760/cma.j.cn501113-20200527-00277.
    [25]
    HSU Y, JUN D, PENG C, et al. Entecavir versus tenofovir disoproxil fumarate for seroclearance of hepatitis B surface antigen in an international real-world cohort[J]. Hepatology, 2021, 74(S1): 434A-436A. DOI: 10.1002/hep.32188.
    [26]
    LU F, FENG B, ZHENG SJ, et al. Current status of the research on low-level viremia in chronic hepatitis B patients receiving nucleos(t)ide analogues[J]. J Clin Hepatol, 2021, 37(6): 1268-1274. DOI: 10.3969/j.issn.1001-5256.2021.06.007.

    鲁凤民, 封波, 郑素军, 等. 核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状[J]. 临床肝胆病杂志, 2021, 37(6): 1268-1274. DOI: 10.3969/j.issn.1001-5256.2021.06.007.
    [27]
    PREVELIGE PE Jr. Inhibiting virus-capsid assembly by altering the polymerisation pathway[J]. Trends Biotechnol, 1998, 16(2): 61-65. DOI: 10.1016/s0167-7799(97)01154-2.
    [28]
    ZLOTNICK A, CERES P, SINGH S, et al. A small molecule inhibits and misdirects assembly of hepatitis B virus capsids[J]. J Virol, 2002, 76(10): 4848-4854. DOI: 10.1128/jvi.76.10.4848-4854.2002.
    [29]
    VENKATAKRISHNAN B, KATEN SP, FRANCIS S, et al. Hepatitis B virus capsids have diverse structural responses to small-molecule ligands bound to the heteroaryldihydropyrimidine pocket[J]. J Virol, 2016, 90(8): 3994-4004. DOI: 10.1128/JVI.03058-15.
    [30]
    TAN Z, PIONEK K, UNCHWANIWALA N, et al. The interface between hepatitis B virus capsid proteins affects self-assembly, pregenomic RNA packaging, and reverse transcription[J]. J Virol, 2015, 89(6): 3275-3284. DOI: 10.1128/JVI.03545-14.
    [31]
    WU G, LIU B, ZHANG Y, et al. Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly[J]. Antimicrob Agents Chemother, 2013, 57(11): 5344-5354. DOI: 10.1128/AAC.01091-13.
    [32]
    YAN Z, WU D, HU H, et al. Direct inhibition of hepatitis B e antigen by core protein allosteric modulator[J]. Hepatology, 2019, 70(1): 11-24. DOI: 10.1002/hep.30514.
    [33]
    LIU H, CHENG J, VISWANATHAN U, et al. Amino acid residues at core protein dimer-dimer interface modulate multiple steps of hepatitis B virus replication and HBeAg biogenesis[J]. PLoS Pathog, 2021, 17(11): e1010057. DOI: 10.1371/journal.ppat.1010057.
    [34]
    FUNG S, CHOI H, GEHRING A, et al. Getting to HBV cure: The promising paths forward[J]. Hepatology, 2022. DOI: 10.1002/hep.32314. [Online ahead of print]
    [35]
    FUNG S, SULKOWSKI M, LALEZARI J, et al. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection[J]. J Hepatol, 2020, 73(S1): S51-S52. DOI: 10.1016/S0168-8278(20)30649-8.
    [36]
    CORNBERG M, LOK AS, TERRAULT NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference[J]. J Hepatol, 2020, 72(3): 539-557. DOI: 10.1016/j.jhep.2019.11.003.
    [37]
    GAO TJ, HAN GY, LU FM. Mechanism relevant to hepatocellular carcinoma occurrence after negative conversion of viral DNA in treatment of chronic hepatitis B patients with nucleos(t)ide drugs[J]. Chin J Hepatol, 2019, 27(11): 905-909. DOI: 10.3760/cma.j.issn.1007-3418.2019.11.017.

    高田敬, 韩耕愚, 鲁凤民. 核苷(酸)类药物治疗慢性乙型肝炎患者病毒DNA阴转后发生肝细胞癌的相关机制[J]. 中华肝脏病杂志, 2019, 27(11): 905-909. DOI: 10.3760/cma.j.issn.1007-3418.2019.11.017.
    [38]
    WANG J, SHEN T, HUANG X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol, 2016, 65(4): 700-710. DOI: 10.1016/j.jhep.2016.05.029.
    [39]
    XIA M, CHI H, WU Y, et al. Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment[J]. Aliment Pharmacol Ther, 2021, 54(5): 709-714. DOI: 10.1111/apt.16538.
    [40]
    YUEN MF, GANE EJ, KIM DJ, et al. Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection[J]. Gastroenterology, 2019, 156(5): 1392-1403. e7. DOI: 10.1053/j.gastro.2018.12.023.
    [41]
    ZOULIM F, LENZ O, VANDENBOSSCHE JJ, et al. JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients With chronic infection[J]. Gastroenterology, 2020, 159(2): 521-533. e9. DOI: 10.1053/j.gastro.2020.04.036.
    [42]
    PATEL N, WHITE SJ, THOMPSON RF, et al. HBV RNA pre-genome encodes specific motifs that mediate interactions with the viral core protein that promote nucleocapsid assembly[J]. Nat Microbiol, 2017, 2: 17098. DOI: 10.1038/nmicrobiol.2017.98.
    [43]
    JUNKER-NIEPMANN M, BARTENSCHLAGER R, SCHALLER H. A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA[J]. EMBO J, 1990, 9(10): 3389-3396. DOI: 10.1002/j.1460-2075.tb07540.x.
    [44]
    GANE E, SULKOWSKI M, MA X, et al. Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection[J]. J Hepatol, 2021, 75(S2): S736. DOI: 10.1016/S0168-8278(21)01843-2.
    [45]
    FUKUTOMI K, HIKITA H, MURAI K, et al. Capsid Allosteric modulators enhance the innate immune response in hepatitis B virus-infected hepatocytes during interferon administration[J]. Hepatol Commun, 2022, 6(2): 281-296. DOI: 10.1002/hep4.1804.
    [46]
    YE J, CHEN J. Interferon and hepatitis B: Current and future perspectives[J]. Front Immunol, 2021, 12: 733364. DOI: 10.3389/fimmu.2021.733364.
    [47]
    FERNÁNDEZ G, L SANCHEZ A, JEREZ E, et al. Five-year follow-up of chronic hepatitis B patients immunized by nasal route with the therapeutic vaccine hebernasvac[J]. Euroasian J Hepatogastroenterol, 2018, 8(2): 133-139. DOI: 10.5005/jp-journals-10018-1279.
    [48]
    GANE E, VERDON DJ, BROOKS AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study[J]. J Hepatol, 2019, 71(5): 900-907. DOI: 10.1016/j.jhep.2019.06.028.
    [49]
    AGARWAL K, BRUNETTO M, SETO WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection[J]. J Hepatol, 2018, 68(4): 672-681. DOI: 10.1016/j.jhep.2017.11.039.
    [50]
    WU Z, XIE D, FU L, et al. Functional cure based on pegylated interferon α in long-term nucleoside analog suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest Project in China), a sequential report - the predictors for HBsAg loss[J]. Hepatology, 2021, 74(S1): 483A. DOI: 10.1002/hep.32188.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (832) PDF downloads(161) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return